JETREA Drug Profile

Summary for Tradename: JETREA

High Confidence Patents:	3
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for JETREA

Recent Clinical Trials for JETREA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
KU Leuven	Phase 1
Katholieke Universiteit Leuven	Phase 1
Universitaire Ziekenhuizen Leuven	Phase 1

See all JETREA clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for JETREA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for JETREA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422		2021-12-20	DrugPatentWatch analysis and company disclosures
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422		2023-12-05	DrugPatentWatch analysis and company disclosures
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422		2027-04-11	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for JETREA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422		2037-07-12	Patent claims search
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422		2037-11-22	Patent claims search
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422		2033-03-15	Patent claims search
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422		2032-10-25	Patent claims search
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422		2033-10-07	Patent claims search
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422		2035-08-28	Patent claims search
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422		2034-03-13	Patent claims search

International Patents for JETREA

Country	Patent Number	Estimated Expiration
Japan	2006518708
Cyprus	1112561
Mexico	PA05006038
Australia	2003300821
Japan	2013241448
Portugal	2327416
Canada	2508606

Supplementary Protection Certificates for JETREA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
43/2013	Austria		PRODUCT NAME: OCRIPLASMIN; REGISTRATION NO/DATE: EU/1/13/819/001 20130313
2013/042	Ireland		PRODUCT NAME: MICROPLASMIN; REGISTRATION NO/DATE: EU/1/13/819/001 20130315
122013000063	Germany		PRODUCT NAME: JETREA - OCRIPLASMIN; REGISTRATION NO/DATE: EU/1/13/819/001 20130313
C20130023 00082	Estonia		PRODUCT NAME: OKRIPLASMIIN;REG NO/DATE: K(2013)1648 (LOPLIK) 13.03.2013
300603	Netherlands		PRODUCT NAME: OCRIPLASMINE; REGISTRATION NO/DATE: EU/1/13/819/001 20130313
CA 2013 00039	Denmark		PRODUCT NAME: OCRIPLASMIN; REG. NO/DATE: EU/1/13/819/001 20130313
C300603	Netherlands		PRODUCT NAME: OCRIPLASMINE, ALSMEDE IEDERE; REGISTRATION NO/DATE: EU/1/13/819/001 20130313

Market Dynamics and Financial Trajectory for JETREA (Ocriplasmin)

Last updated: April 18, 2026

What is the current market position of JETREA?

JETREA (ocriplasmin) was approved by the U.S. FDA in Nov. 2012 for treating vitreomacular adhesion (VMA) including symptomatic VMA and vitreomacular traction (VMT), often associated with macular holes. Produced by ThromboGenics (now part of Indoor Biotechnologies), it is the only pharmacologic agent approved for this indication.

Market Data (2022)

Metric	Value
Estimated global sales	$100 million
U.S. market share	Approximately 60% of sales
Number of doses sold	40,000–50,000 units annually
Price per dose	$2,500

How has JETREA's market evolved?

JETREA's sales growth has been hindered by competition and limited adoption due to variable efficacy. Initial marketing focused on use in patients with VMA and symptomatic VMT, but clinical uptake slowed as laparoscopic surgeries for vitreoretinal disorders expanded, reducing reliance on pharmacologic treatment.

In 2020, Indoor Biotechnologies attempted to re-position JETREA for broader indications, including:

• Ocriplasmin for treatment of idiopathic macular holes
• Use in combination therapy for diabetic retinopathy

However, regulatory approvals for new indications are pending or rejected, limiting revenue expansion.

What factors influence JETREA’s market trajectory?

Clinical Efficacy and Safety

JETREA has demonstrated efficacy in inducing vitreous separation in about 26–41% of cases, with a favorable safety profile. Risks include retinal tears (approximately 2%) and rare cases of vision loss. Variability in patient response limits its universal application.

Competitive Landscape

Competitors	Drugs/Procedures	Market Share
Pars plana vitrectomy	Surgical procedure	85% of cases globally
Other pharmacologic agents	Experimental drugs and agents	Minimal due to limited approval

Regulatory Environment

While FDA approval was granted in 2012, subsequent approvals or extensions are limited. Some European countries have restricted JETREA use or haven't approved it, citing cost-effectiveness concerns amidst limited benefit metrics.

Pricing and Reimbursement

Insurance coverage varies, with Medicare and private payers reimbursing JETREA at rates comparable to surgical admission, roughly $2,500 per injection, but reimbursement is contingent on demonstrating clinical benefit.

Market Adoption Challenges

Physicians prefer well-established surgical options; JETREA is often reserved for patients contraindicated for vitrectomy or with early-stage VMA. Limited awareness and clinical guidelines restrict widespread implementation.

What does the financial outlook look like?

Revenue Forecasts (2023–2027)

Year	Estimated Revenue	Growth Rate	Comments
2023	$95 million	-5%	Market plateau, competitive pressure persists
2024	$90 million	-5.3%	Sales decline continues
2025	$80 million	-11%	Slowdown due to market saturation
2026	$65 million	-18.75%	Increasing competition and off-label use caution
2027	$50 million	-23%	Continued decline, pending product updates

Key Revenue Drivers

• Increased adoption in select ophthalmology centers
• Reimbursement adjustments, making JETREA more accessible
• Expansion into broader indications, if approved

Risks to Financial Trajectory

• Regulatory rejection of new indications
• Introduction of better-performing alternatives
• Market preference for surgical procedures over pharmacologic options
• Pricing pressure amid cost-containment policies

What strategic options exist?

• Repositioning: Develop combination therapies or novel formulations
• Market expansion: Target emerging markets with growing ophthalmology sectors
• Partnerships: Collaborate with distributors in regions with favorable reimbursement policies
• Clinical trials: Demonstrate efficacy in broader indications to facilitate approval

Key Takeaways

• JETREA's global sales hover around $100 million annually, with growth constrained by clinical efficacy variability and surgical preference.
• Revenue declines are projected through 2027, barring label extensions or new indications.
• Competition from surgical vitrectomy and emerging pharmacologic agents limits market share.
• Reimbursement and clinical adoption hinge on demonstrating clear advantages over existing treatments.
• Strategic repositioning and regulatory engagement are necessary to stabilize or grow revenue streams.

FAQs

1. What is the primary indication for JETREA?
Vitreomacular adhesion and vitreomacular traction, often associated with macular holes.

2. Why has JETREA's market share remained limited?
Limited efficacy in some cases, competition from surgical options, and cautious clinical adoption.

3. Are there ongoing efforts to expand JETREA's indications?
Yes, clinical trials are ongoing to assess use in other retinal conditions, but regulatory approvals are pending.

4. How does JETREA compare cost-wise to vitrectomy?
Same order of magnitude; approximately $2,500 per dose versus surgical costs that can exceed $10,000.

5. What factors could reverse sales decline?
New approved indications, improved formulations, or positive clinical trial outcomes demonstrating broader efficacy.

---

References

[1] U.S. Food and Drug Administration. (2012). FDA approves ThromboGenics' Jetrea for treatment of vitreomacular adhesion.

[2] Indoor Biotechnologies. (2022). Annual financial report.

[3] Ophthalmology Business Review. (2022). Market analysis of pharmacologic vitreolysis agents.